Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Pancreatic tumor progression suppressed by promoter driven Bik mutant
July 14th, 2006
Recent research from the United States has reported that pancreatic tumor progression is suppressed by systemic delivery of a pancreatic-cancer-specific promoter (PCSP) driven Bik mutant. "Pancreatic cancer is highly aggressive with extremely poor prognosis. Developing a PCSP is one approach for pancreatic cancer gene therapy," wrote Z. Li and colleagues, M.D. Anderson Cancer Center. "We have modified the promoter of cholecystokinin type A receptor (CCKAR), named CCK/Mpd, which possesses a relatively high activity in pancreatic cancer cells as compared with normal cells. "The CCK/Mpd promoter-driven luciferase exhibits a better...
Source: Genomics & Genetics Weekly (2006-07-14)
|
